This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold.

Houdini Bio has announced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from an oversubscribed pre-seed round.

The funding enables Houdini Bio to validate its technology and achieve projected technical milestones in a third of the predicted time. The platform- a machine learning-guided DNA sequence design infrastructure- is engineered to overcome the biological barriers limiting genetic medicines.

Positioned for rapid commercial scaling ahead of its next funding round, Houdini Bio provides the infrastructure required to make genetic medicines work durably, consistently and cost-efficiently at scale- transform ...